March 5 - ALX Oncology: As the biotech looks to channel its cash into further trials of its CD47 blocker, the company will lay off 30% of its ... As the major cost-cutting initiative at BMS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback